Ulcerative Colitis Pipeline Summary

DelveInsight’s, “Ulcerative Colitis - Pipeline Insight, 2026” report provides comprehensive insights about 115+ companies and 120+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ulcerative Colitis: Understanding

Ulcerative Colitis: Overview

Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by diffuse inflammation, superficial erosions, and ulceration of the colon. The inflammation is primarily limited to the mucosa and submucosa and typically begins in the rectum before extending proximally in a continuous pattern. UC follows a relapsing-remitting course and commonly presents with bloody diarrhea, abdominal pain, urgency, and tenesmus.

The exact cause of UC remains unknown, but it is thought to result from a combination of genetic susceptibility, abnormal immune responses, alterations in the gut microbiota, and defects in the intestinal mucosal barrier. A family history of UC is an important risk factor, while dysregulated mucosal immunity and an abnormal immune response to normally non-pathogenic intestinal bacteria are also considered contributors.

UC involves disruption of the colonic epithelial barrier, altered gut microbiota, and an inappropriate immune response. Defects in mucin and tight-junction function can increase exposure of the mucosa to luminal antigens, triggering activation of immune cells. This promotes inflammatory signaling involving mediators such as tumor necrosis factor-alpha (TNF-?) and interleukin-13, along with increased leukocyte recruitment into the colonic mucosa. The resulting persistent inflammation causes epithelial injury, crypt abnormalities, ulceration, and depletion of goblet cells.

Diagnosis is based on clinical presentation together with endoscopic and histological findings and exclusion of infectious causes. Stool testing is performed to rule out bacterial and parasitic infections. Colonoscopy or proctosigmoidoscopy typically demonstrates loss of the vascular pattern, mucosal granularity and friability, erosions, and ulceration in a continuous pattern beginning in the rectum. Multiple biopsies are obtained for histological confirmation. Laboratory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fecal calprotectin can support assessment of inflammation, although they are not specific for UC.

Treatment is determined by disease extent and severity, with the goals of inducing and maintaining remission and preventing complications. Mild-to-moderate disease is commonly treated with 5-aminosalicylates (5-ASAs), administered orally and/or rectally, while corticosteroids may be used to induce remission when 5-ASAs are insufficient. Patients with refractory disease may require immunosuppressants such as azathioprine or 6-mercaptopurine and biologic therapies, including anti-TNF agents such as infliximab, adalimumab, and golimumab, or the anti-integrin agent vedolizumab. Colectomy can provide a definitive cure for colonic disease and is considered for medically refractory or complicated UC, including fulminant colitis, toxic megacolon, perforation, severe bleeding, dysplasia, or colorectal cancer.

"Ulcerative Colitis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ulcerative Colitis pipeline landscape is provided which includes the disease overview and Ulcerative Colitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative Colitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative Colitis.

Ulcerative Colitis Emerging Drugs Chapters

This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ulcerative Colitis Emerging Drugs

• Duvakitug: Teva Pharmaceuticals/Sanofi

Duvakitug is a potential best-in-class human IgG1-?2 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15 (TNFSF15). TL1A signaling is believed to amplify inflammation and drive fibrosis associated with inflammatory bowel disease (IBD) through binding its receptor, death receptor 3 (DR3). Duvakitug is uniquely designed to inhibit preferentially TL1A signaling via DR3, with the potential advantage of reduced TL1A-DcR3 inhibition. Teva pharmaceuticals and Sanofi are collaborating to co-develop and co-commercialize Teva’s duvakitug for the treatment of UC and CD. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a royalty arrangement. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Ulcerative Colitis.

• Zasocitinib: Takeda

Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways.15-19 It has the potential to be a leading oral treatment option for people living with psoriasis that may deliver rapid and durable skin clearance in a convenient once-daily pill.20 Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Ulcerative Colitis.

• ALTB-268: AltruBio

ALTB-268 is a subcutaneously administered, tetravalent agonist antibody targeting PSGL-1, a key immune checkpoint regulator. It acts as an immune checkpoint enhancer (ICE), preferentially downregulating chronically activated late-stage T effector cells, leading to their exhaustion and/or apoptosis. The drug is designed to activate natural pathways that downregulate a chronically overactivated immune system to restore balance. ALTB-268 operates through a unique mechanism of action, targeting PSGL-1, a key immune checkpoint regulator. It preferentially targets and downregulates chronically activated late-stage effector T cells, leading to their exhaustion and apoptosis. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Ulcerative Colitis.

• OD-001: Odyssey Therapeutics

OD-001 is an oral small molecule RIPK2 scaffolding inhibitor. We believe that blocking RIPK2 scaffolding with XIAP has the potential to block downstream pathway signaling and activation of proinflammatory cells of both the innate and adaptive immune systems that drive pathology and produce high levels of cytokines (e.g., TNF, TNF-like cytokine 1A, or TL1A, and interleukin 23) that each are validated therapeutic targets for inflammatory bowel disease (IBD). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Ulcerative Colitis.

• PALI-2108: Palisade Bio

PALI-2108 is a once-daily, orally administered PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, where bacterial ?-glucuronidase cleaves the prodrug to release the active PDE4 inhibitor, enabling localized PDE4 inhibition at sites of intestinal inflammation while limiting systemic exposure. By inhibiting PDE4, PALI-2108 prevents the breakdown of intracellular cyclic AMP (cAMP), resulting in increased cAMP levels and suppression of inflammatory signaling and immune-cell infiltration in the intestinal tissue. The company states that this gut-targeted mechanism is intended to maintain anti-inflammatory activity while reducing the GI and CNS adverse effects associated with systemic PDE4 inhibitors. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Ulcerative Colitis.

• R-3750: Rise Therapeutics

R-3750, a novel oral immunotherapy, is a synthetic biology-based medicine optimized to selectively target dendritic cells, R-3750 is a first-in-class therapy with a unique mechanism of action with the potential to treat the underlying immunological basis of gastrointestinal inflammatory diseases. Dysfunctional immune control is an important underlying mechanism driving IBD. Extensive preclinical studies on R-3750 demonstrated targeting of a specific dendritic cell receptor which promotes regulatory T cell (Treg) induction, reduces gut inflammation, and improves gut membrane barrier integrity. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Ulcerative Colitis.

Further product details are provided in the report……..

Ulcerative Colitis: Therapeutic Assessment

This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Ulcerative Colitis

There are approx. 100+ key companies which are developing the therapies Ulcerative Colitis. The companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Phase III include, Teva Pharmaceuticals, and others.

• Phases

DelveInsight’s report covers around 105+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ulcerative Colitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.

Ulcerative Colitis Report Insights

• Ulcerative Colitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ulcerative Colitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ulcerative Colitis drugs?
• How many Ulcerative Colitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative Colitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ulcerative Colitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Teva Pharmaceuticals
• Takeda
• Sorriso Pharmaceuticals
• Merck & Co., Inc
• Eli Lilly and company
• Johnson & Johnson
• Accro Bioscience
• Sanofi
• Rise Therapeutics
• AltruBio Inc.
• Odyssey Therapeutics
• PALATIN
• Adial Pharmaceuticals
• Roche
• Spyre Therapeutics
• Pallisade Bio
• Vanda Pharmaceuticals
• Ono Pharmaceuticals
• Xencor Inc.

Key Products

• Davakitug (TEV-574)
• Zasocitinib
• SOR102
• MK-8690
• Eltrekibart
• JNJ-78934804
• AC-101
• R-3750
• ALTB-268
• OD-001
• PL8177
• AT 177
• Afimkibart
• Ponesimod
• ONO-6414
• SPY001
• PALI-2108
• XmAb942
• SPY002
• SPY003
• SPY130
• SPY120
• SPY230